ÂÜÀòÂÒÂ×

Martin Ostrowski is currently the Chief Technology Officer at Kenai Therapeutics, a biotechnology company focused on neuron replacement therapies. Prior to this role, Martin was the President & COO at Dianomi Therapeutics and the Founder & Chief Technology Officer at Vascugen. With a background in biochemistry and bioengineering, Martin has also held roles at companies like Chelon Therapeutics and CELLSCRIPT. Additionally, Martin has experience in business development, intellectual property, and as an intellectual property attorney.